- Home
- JNVR vs PRPO Comparison
JNVR vs PRPO Comparison
Compare JNVR & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JNVR
- PRPO
- Stock Information
- Founded
- JNVR 2018
- PRPO N/A
- Country
- JNVR United States
- PRPO United States
- Employees
- JNVR N/A
- PRPO 57
- Industry
- JNVR Finance: Consumer Services
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- JNVR Finance
- PRPO Industrials
- Exchange
- JNVR Nasdaq
- PRPO Nasdaq
- Market Cap
- JNVR N/A
- PRPO 9.5M
- IPO Year
- JNVR 2023
- PRPO N/A
- Fundamental
- Price
- JNVR $0.55
- PRPO $6.59
- Analyst Decision
- JNVR
- PRPO
- Analyst Count
- JNVR 0
- PRPO 0
- Target Price
- JNVR N/A
- PRPO N/A
- AVG Volume (30 Days)
- JNVR 21.7K
- PRPO 7.9K
- Earning Date
- JNVR 11-12-2024
- PRPO 11-11-2024
- Dividend Yield
- JNVR N/A
- PRPO N/A
- EPS Growth
- JNVR N/A
- PRPO N/A
- EPS
- JNVR N/A
- PRPO N/A
- Revenue
- JNVR $1,786,085.00
- PRPO $16,719,999.00
- Revenue This Year
- JNVR N/A
- PRPO $75.18
- Revenue Next Year
- JNVR N/A
- PRPO N/A
- P/E Ratio
- JNVR N/A
- PRPO N/A
- Revenue Growth
- JNVR N/A
- PRPO 52.61
- 52 Week Low
- JNVR $0.42
- PRPO $4.31
- 52 Week High
- JNVR $1.84
- PRPO $8.99
- Technical
- Relative Strength Index (RSI)
- JNVR 49.64
- PRPO 52.82
- Support Level
- JNVR $0.49
- PRPO $6.42
- Resistance Level
- JNVR $0.62
- PRPO $6.99
- Average True Range (ATR)
- JNVR 0.06
- PRPO 0.33
- MACD
- JNVR -0.00
- PRPO -0.04
- Stochastic Oscillator
- JNVR 58.69
- PRPO 69.91
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.